Senses Disorder TRIZ Cases

Novel pyrrolidine beta-3 adrenergic receptor agonists relax the detrusor muscle to treat overactive bladder conditions.

GDF15 blocks Smad2 activation and Fibronectin expression, resolving poor visual recovery after retinal detachment surgery.

C-terminal peptides block apoptotic pathways via protein transduction domains, preventing retinal ganglion cell death despite persistent intraocular pressure.

A C2c1 nuclease paired with optimized guide RNA enables precise genome editing in mammalian cells.

Novel trifluorocarbamate derivatives inhibit monoacylglycerol lipase to treat pain and inflammatory disorders.

N-containing heteroaryl derivatives inhibit JAK3 kinase activity to resolve the trade-off between therapeutic efficacy and side effects.

Substituted amino triazole compounds inhibit AMCase and CHIT1 while avoiding hERG channel binding to prevent cardiotoxicity.

Irregular microparticle plugs adsorb benzalkonium chloride while maintaining hydraulic permeability to prevent ocular toxicity.

Engineered atoxic neurotoxin derivatives eliminate N-terminal cargo attachment peptides to preserve therapeutic muscle paralysis while removing toxic enzymatic activity.

Glycerol eye drops remove excess fluid from conjunctival tissue to eliminate folds and avoid surgical intervention.

3,5-diaminopyrazole compounds selectively inhibit regulated-in-COPD kinase while avoiding Janus kinase off-target effects.

CaMKII inhibitors regulate kinase activity to treat cardiovascular diseases where lifestyle modifications fail.

Multimodal cation and anion exchange combined with hydrophobic interaction chromatography removes host cell proteins and DNA from heavily glycosylated lubricin.

PEGylated cystathionine beta-synthase polypeptide overcomes Vitamin B6 non-responsiveness to lower serum homocysteine levels.

Combining a glucopyranosyl-substituted benzene derivative with a DPP IV inhibitor enhances glycemic control through dual mechanism action.

Modified pyrrolidine compounds restore gap junction integrity, resolving peptide instability and poor oral bioavailability.

Segmented bead populations with release-controlling coatings deliver topiramate to reduce peak plasma concentrations and side effects.

Targeting conserved Protein E resolves antigenic diversity in non-typeable Haemophilus influenzae strains, providing broad protection against infections.

Deuterated retinol compounds scavenge toxic aldehydes, addressing treatment gaps in ocular and skin disorders.

Modified capsid proteins increase infectivity by crossing the inner limiting membrane, resolving low delivery efficiency in retinal treatments.

Chimeric peptides merge trafficking and inhibitor sequences to block JNK signaling, treating cystitis via intravesical delivery.

Indane derivatives target HIF-2α pathways to treat renal cancer and inflammatory disorders while sparing HIF-1α to reduce unintended toxicity.

Phenyl compounds inhibit beta-secretase and gamma-secretase enzymes to reduce amyloid beta levels.

Heterocyclic IC-GPCR2 agonists trigger cAMP-mediated glucose-dependent insulin release, resolving hypoglycemia risks inherent in sulphonylurea treatments.

A drippable ophthalmic gel formulation enhances ocular bioavailability of bimatoprost without preservatives.

Inhibiting FBXO3 prevents TRAF protein degradation, resolving inadequate cytokine modulation in respiratory diseases.

A homogeneous aqueous solution combines moxifloxacin, dexamethasone, and bromfenac into a single topical application.

Pyrazolylbenzimidazole derivatives enhance anticancer activity while reducing side effects through localized molecular interactions.

Bacterial-expressed Fyn SH3 polypeptides replace complex antibodies to inhibit IL-17A without aggregation or immune responses.

HMG CoA reductase inhibitors lower meibum cholesterol to improve tear film stability without relying on anti-inflammatory treatments.

Composite formulations with polyunsaturated fatty acid monoglycerides resolve poor water solubility of lipophilic drugs, improving oral absorption.

Covalent conjugation of cannabinoids to hyaluronic acid resolves low aqueous solubility and stability issues in oral delivery systems.

Indane derivatives activate oxidized soluble guanylate cyclase to modulate intraocular pressure.

Phthalazine derivatives inhibit PCAF and GCN5 bromodomains, delaying resistance development in cancer therapy.

Oral Lactobacillus reuteri Y7 reduces oxidative stress and inflammation to treat blue light-induced macular disease.

Retinoic acid receptor agonists activate endogenous stem cells to regenerate rod photoreceptors, avoiding immune rejection from cell transplants.

Substituted piperidinyltetrahydroquinolines act as selective adrenoreceptor alpha2C antagonists to modulate vascular activity.

HM-3 and interleukin 4 fusion with IgG1 Fc fragment extends circulation half-life, reducing administration frequency for tumor treatment.

AAV vectors deliver TXNIP to up-regulate LDHB, rescuing cones despite genetic heterogeneity.

Sirolimus eye drops suppress meibomian gland obstruction, resolving chronic ocular discomfort and telangiectasia.

A semifluorinated alkane liquid vehicle dissolves ciclosporin for topical ocular administration.

Enzymatic hydrolysis of simmondsin glucosides enables targeted release in the small intestine, reducing gastric side effects.

Segmented oxadiazole structures block tryptophan degradation pathways that suppress immune responses in cancer treatment.

Dual-site acylation of GLP-1 analogues extends half-life while maintaining potency, enabling once-monthly administration.